cAMP regulates 11β-hydroxysteroid dehydrogenase-2 and Sp1 expression in MLO-Y4/MC3T3-E1 cells

DI LIU, YAOQING WANG, ZHENYU PAN, ZHEN HUANG and FAN CHEN

Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China

Received July 20, 2019; Accepted March 26, 2020

DOI: 10.3892/etm.2020.8942

Abstract. 11β-hydroxysteroid dehydrogenase-2 (11β-HSD2) is one of the key enzymes in glucocorticoid metabolism, which can inactivate local corticosterone and regulate the level of active glucocorticoid in tissues. The expression of 11β-HSD2 and its regulatory pathway serve an important role in the apoptosis of steroid induced osteonecrosis of the femoral head (SANFH). The present study aimed to identify the regulatory effects of cAMP on the expression of Sp1 transcription factor (Sp1) and 11β-HSD2 in osteocytes at the cellular level. Murine long bone osteocyte Y4 (MLO-Y4) clone cells and mouse embryo osteoblast-like (MC3T3-E1) cells were cultured in vitro with adenylyl cyclase activator or inhibitor (forskolin and SQ22536, respectively) to investigate the effects of alterations to intracellular cAMP levels. mRNA and protein expression levels of Sp1 and 11β-HSD2 were detected by reverse transcription-quantitative PCR and western blotting, respectively. Compared with the negative control group, the mRNA and protein expression levels of Sp1 were significantly increased in the activation group, whereas 11β-HSD2 expression levels were significantly decreased in the inhibition group. Similarly, compared with the negative control group, the mRNA and protein expression levels of 11β-HSD2 were significantly increased in the activation group, but significantly decreased in the inhibition group. The aforementioned results indicated that intracellular cAMP levels significantly regulated the expression of Sp1 and 11β-HSD2 in mouse osteocytes and osteoblasts. Therefore, the present study suggested a potential therapeutic strategy for the prevention of osteonecrosis of the femoral head.

Introduction

Steroid-induced avascular necrosis of the femoral head (SANFH) is a serious orthopedic disease associated with the clinical application of steroid hormones, characterized by progressive osteonecrosis leading to structural alterations to the femoral head, which can ultimately result in femoral head collapse (1). According to the duration and dosage of the steroid hormone, femoral head necrosis occurs in 5-40% of patients a few years after the onset of the disease (2-4). Although the mechanism underlying ischemic necrosis of the femoral head is not completely understood (1), the mechanism underlying osteocyte apoptosis has received increased attention (5-8). Glucocorticoid-induced osteocyte apoptosis is a cumulative and irreparable deficiency defect that destroys the mechanical sensory function of the osteocyte-lacunar-tubule system, thereby initiating a succession of events that inevitably lead to joint collapse (9). A possible mechanism resulting in apoptosis is that the long-term use of glucocorticoids can lead to excessive oxidative stress, which may activate apoptosis-associated signaling pathways when the antioxidant capacity of the cells is exceeded (6). Another study demonstrated that glucocorticoids are able to induce apoptosis via Dickkopf-1 (DKK-1)-mediated blocking of the Wnt/β-catenin signaling pathway, a process that reduces osteoblast proliferation, activates apoptosis and induces osteoclast differentiation and maturation, subsequently disrupting bone homeostasis and leading to a series of bone diseases, including osteoporosis and osteonecrosis (10). DKK-1 regulates myeloma bone disease by disrupting osteoblast differentiation and function. A study conducted by Lu et al (11) described a DKK1 vaccine that displayed therapeutic effects against the established disease via induction of active immunity. However, apoptosis is mediated by the strict control of multiple genes, which involves the activation, expression and regulation of a series of genes.

Correspondence to: Professor Zhenyu Pan, Department of Orthopedics, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, P.R. China E-mail: soloistp@126.com

Key words: osteonecrosis, apoptosis, protein expression, Sp1 transcription factor, glucocorticoid
inactive metabolites (14,15), thereby preventing the body from accumulating large amounts of active hormones. 11β-HSD2 is widely distributed in tissues such as the kidney, placenta, heart and colon (16); therefore, it has been hypothesized that low expression levels of 11β-HSD2 are unfavorable to the body.

Several overlapping binding sites for Sp1 transcription factor (Sp1) have been identified in multiple CpG islands in the promoter region of 11β-HSD2 (17). Sp1 is a member of the zinc-finger transcription factor family that binds to a consistent promoter site, including a central CpG dinucleotide (18,19). In particular, Sp1 specifically binds to the promoter region of 11β-HSD2 and recruits the transcriptional co-activator p300, which affects histone acetylation modification of the 11β-HSD2 promoter region, by increasing H3K9Ac and decreasing H3K9me2, to promote the expression of 11β-HSD2 (20). Wang et al (21) reported that cortisol-induced aromatase is expressed in human placental syncytiotrophoblast cells via the cAMP/Sp1 signaling pathway. A previous study demonstrated that the tissues of the femoral head also expressed 11β-HSD, and in a model of steroid-induced osteonecrosis of the femoral head, the expression of 11β-HSD1 was increased, whereas the expression of 11β-HSD2 was decreased, which lead to further increases in the local GC concentration of the femoral head tissue (22). Therefore, the present study aimed to investigate the effects of altering cAMP levels on the expression of Sp1 and 11β-HSD2 in osteocytes and osteoblasts.

Materials and methods

Cell culture and grouping. MLO-Y4 cells were purchased from Procell Life Science & Technology Co., Ltd and MC3T3-E1 cells were purchased from iCell. MLO-Y4 cells can be used as representative models of primary osteocytes (23) and MC3T3-E1 cells are a reliable substitute as models of primary osteocytes (24) and osteoblasts (25). Cells were cultured in MEM-α medium (HyClone; GE Healthcare Life Sciences) containing 10% FBS (Zhejiang Tianhang Biotechnology Co., Ltd.) and 1% penicillin/streptomycin at 37˚C with 5% CO₂. MC3T3-E1 cells were purchased from iCell. MLO-Y4 cells can be used as representative models of primary osteocytes (23) and MC3T3-E1 cells are a reliable substitute in vitro model of human osteoblasts (24). Cells were cultured in MEM-α medium (HyClone; GE Healthcare Life Sciences) containing 10% FBS (Zhejiang Tianhang Biotechnology Co., Ltd.) and 1% penicillin/streptomycin at 37˚C with 5% CO₂. At 80% confluence, cells were subcultured. Trypsin-EDTA (0.25% trypsin and 0.02% EDTA; Genom Biotech Pvt., Ltd.) was added to the cells for digestion purposes. Subsequently, the cell layer was inhibited and observed under a light microscope (magnification, x20) until the cells became round and dispersed. The cell suspension was centrifuged at 300 x g for 5 min at room temperature, the supernatant was discarded and the cells were suspended in fresh MEM-α medium. Cells were subsequently cultured at 37˚C with 5% CO₂. Cells in the exponential phase of growth were seeded into 6-well plates with 2x10⁵ cells per well. The blank group consisted of wells containing 10 µl cell-free medium only. Following incubation at 37˚C for 24 h, 10 µl CCK-8 solution (Shanghai Rebiosci Biotech Co., Ltd.) was added to each well at 37˚C for 3 h. The absorbance of each well was measured at a wavelength of 450 nm using an ELISA reader (Diatek Healthcare Pvt. Ltd.).

Quantitative determination of cAMP levels in each group by ELISA. Cells were centrifuged at 2,000 x g at 4˚C for 10 min to remove insoluble cell debris. Subsequently, the supernatant was separated and analyzed using the mouse cAMP ELISA kit [cat. no. ELK8116; Elk (Wuhan) Biotechnology Co. Ltd.], according to the manufacturer's protocol.

RNA extraction and RT-qPCR. Cells were washed with pre-cooled PBS. Total RNA was extracted using TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.). Subsequently, total RNA was reverse transcribed into cDNA using the PrimeScript™ RT reagent kit with genomic (g)DNA Eraser (Clontech Laboratories, Inc.) according to the manufacturers' protocol. To remove gDNA, the reaction was performed on ice. Subsequently, qPCR was performed on a StepOne™ Real-Time PCR machine (Thermo Fisher Scientific, Inc.) using the SYBR® Premix Ex Taq™ kit (Clontech Laboratories, Inc.) with three replicate wells per sample. The following thermocycling conditions were used for qPCR: Incubation at 95˚C for 1 min; followed by 40 cycles of 95˚C for 15 sec, 58˚C for 20 sec and 72˚C for 45 sec. The primers used for qPCR were synthesized by Wuhan GeneCreate Biological Engineering Co., Ltd. and are presented in Table I. Following qPCR, agarose gel (2.0%) electrophoresis of the PCR products was performed to observe band intensity. mRNA expression levels were quantified using the 2−ΔΔCq method and normalized to the internal reference gene GAPDH (25). RT-qPCR was performed in triplicate.

| Gene          | Sequence (5’-3’)                  | PCR product size, bp |
|---------------|-----------------------------------|----------------------|
| GAPDH         | F: TGAAGGTTGAGCCAAAAG              | 227                  |
|               | R: AGCTTCTTTGGGTCAGTGAT            |                      |
| Sp1           | F: AACCTTCAGTGGTTGACCTTTCC         | 164                  |
|               | R: CTATCTTCTTCCTCCACCTGC           |                      |
| 11βHSD2       | F: TGCTTCAAGACAGATGCGTACGGAC       | 175                  |
|               | R: CAACTTGAGCCTAAGGGTACG          |                      |

Sp1, Sp1 transcription factor; 11βHSD2, 11β hydroxysteroid dehydrogenase 2; F, forward; R, reverse.
Protein extraction and western blotting. Total protein was extracted from cells using RIPA protein lysate (Wuhan Aspen Biotechnology Co., Ltd.) and quantified using a bicinchoninic acid protein concentration assay kit (Wuhan Aspen Biotechnology Co., Ltd.). Subsequently, the protein expression levels of 11β-HSD2 and Sp1 were detected following a standard western blotting protocol. Proteins (40 µg) were added to an appropriate amount of protein loading buffer (5X) and incubated at 95-100˚C in a boiling water bath for 5 min. Subsequently, proteins were separated via 8% SDS-PAGE and transferred onto methanol pre-activated PVDF membranes (EMD Millipore). The membranes were blocked with 5% non-fat milk at room temperature for 1 h. Subsequently, the membranes were incubated overnight with the following primary antibodies: Anti-Sp1 (cat. no. ab227383; 1:5000; Abcam), anti-11β-HSD2 (cat. no. ab80317; 1:1,000; Abcam) and anti-GAPDH (cat. no. ab37168; 1:10,000; Abcam). After washing three times with TBS containing the 0.05% of Tween-20 (TBST), the membranes were incubated with the corresponding horseradish peroxidase-conjugated secondary antibody (cat. no. AS1107; 1:10,000; Wuhan Aspen Biotechnology Co., Ltd.) for 30 min. Protein bands were visualized using the ECL system (Thermo Fisher Scientific, Inc.). The optical density of the target bands was assessed using the AlphaEaseFC™ 4.0 software processing system (ProteinSimple) with GAPDH as the loading control. Western blotting was performed in triplicate.

Statistical analysis. All experiments were performed at least three times. Data are presented as the mean ± SEM. One-way ANOVA followed by Tukey’s post hoc test was used to analyze the cell viability data. One-way ANOVA followed by the Student-Newman-Keuls post hoc test was used to analyze the ELISA, RT-qPCR and western blotting data. Statistical analyses were performed using GraphPad Prism software (version 5; GraphPad Software, Inc.). P<0.05 was considered to indicate a statistically significant difference.

Results
Effects of forskolin and SQ22536 on MLO-Y4/MC3T3-E1 cell activity. The effects of forskolin and SQ22536 on MLO-Y4 and MC3T3-E1 cell viability were assessed using the Cell
Counting Kit-8 assay (Fig. 1). Compared with the 0 µmol forskolin group, cell viability was increased in the 10 µmol forskolin group following incubation for 24 h (P>0.05). Cell viability in the 50, 100 and 200 µmol forskolin groups was significantly increased compared with the 0 µmol forskolin group (P<0.05). However, the 100 µmol forskolin group displayed the most significant increase in cell viability compared with the 0 µmol forskolin group; therefore, 100 µmol forskolin was selected for subsequent experiments (Fig. 1A). Furthermore, compared with the 0 µmol SQ22536 group, cell viability was significantly decreased in the 100 and 200 µmol SQ22536 groups (P<0.001), but there was no significant difference between the two groups (P>0.05); therefore, 100 µmol SQ22536 was selected for subsequent experiments (Fig. 1B).

Detection of cAMP expression in MLO-Y4 and MC3T3-E1 cells by ELISA. Subsequently, whether forskolin and SQ22536 had a significant effect on the expression of cAMP in MLO-Y4 and MC3T3 -E1 cells was investigated. Compared with the NC group, the content of cAMP in the activator group was significantly increased (P<0.05), whereas the content of cAMP was significantly decreased in the inhibitor group (P<0.01). The results suggested that the adenylate cyclase activator and inhibitor significantly upregulated and downregulated the content of cAMP, respectively, in mouse osteoblast-like and bone-like cells (Fig. 2).

Sp1 and 11β-HSD2 expression levels in MLO-Y4 and MC3T3 -E1 cells. The effect of upregulation and downregulation of cAMP content on the expression levels of Sp1 and 11β-HSD2 were detected by RT-qPCR (Fig. 3). The expression levels of Sp1 and 11β-HSD2 were significantly increased in the activator group compared with the NC group (P<0.05). By contrast, the expression levels of Sp1 and 11β-HSD2 in the inhibitor group were significantly decreased compared with the NC group (P<0.05).

Protein expression levels of Sp1 and 11β-HSD2. Western blotting was performed to detect whether alterations to cAMP content had an effect on the expression levels of Sp1 and 11β-HSD-2 (Fig. 4). The expression levels of Sp1 and 11β-HSD2 in the activator group were significantly increased compared with the NC group (P<0.05). Moreover, the expression levels of Sp1 and 11β-HSD2 were significantly decreased in the inhibitor group compared with the NC group (P<0.05).

Discussion

The results of the present study supported the hypothesis that, compared with the negative control group, the relative expression of Sp1 and 11β-HSD2 in the activator group was significantly increased. In contrast, the relative expression of Sp1 and 11β-HSD2 in the inhibitor group was significantly decreased compared with the negative control group. Specifically, the data indicated that upregulating or downregulating intracellular cAMP levels in MLO-Y4 and MC3T3 -E1 cells increased or decreased the expression levels of Sp1 and 11β-HSD2, respectively. Therefore, the results suggested that in osteoblasts and osteocytes, cAMP mediated the expression of the transcription stimulator Sp1 and the glucocorticoid -regulated key enzyme 11β-HSD2, which is closely related to SANFH-associated apoptosis.

Increasing evidence has suggested that activation of the cAMP signaling pathway serves an important role in hormone metabolism. Cabrera-Sharp et al (26) reported that cortisol-cortisone metabolism in boar testis and caput epididymis could be regulated by the cAMP-protein kinase A (PKA) signaling pathway via their selective effects on the reductase activity of 11β-HSD. Prenatal ethanol exposure

Figure 3. Sp1 and 11β-HSD2 expression levels in MLO-Y4 and MC3T3-E1 cells. (A) Sp1 mRNA expression levels in MLO-Y4 and MC3T3-E1 cells. Compared with the NC group, the expression of Sp1 was significantly reduced in the inhibitor group (P<0.01). By contrast, the expression of Sp1 was significantly increased in the activator group compared with the NC group (P<0.001) and MC3T3-E1 cells (P<0.01). (B) 11β-HSD2 mRNA expression levels in MLO-Y4/MC3T3-E1 cells. In MLO-Y4 cells, compared with the NC group, the expression of 11β-HSD2 in the inhibitor and activator groups was decreased and increased, respectively (P<0.05). Compared with the NC group, the expression of 11β-HSD2 in MC3T3-E1 cells was significantly decreased in the inhibitor group (P<0.001), and significantly increased in the activator group (P<0.01). **P<0.05, ***P<0.01, ****P<0.001 vs. NC. Sp1, Sp1 transcription factor; 11β-HSD2, 11β-hydroxysteroid dehydrogenase-2; NC, negative control.
reduced placental 11β-HSD2 expression, which was controlled via the mechanism underlying ethanol-induced histone modification alterations to the 11β-HSD2 promoter via the cAMP/PKA signaling pathway (27). However, biological analysis of the promoter sequence of the 11β-HSD2 gene indicated that the 11β-HSD2 promoter did not contain a cAMP-response element; therefore, the effect of cAMP on the expression of 11β-HSD2 was potentially indirectly mediated via other transcription factors (28). Sp1 is a sequence-specific DNA-binding protein that regulates the transcription of cellular and viral genes containing GC-rich promoters (29). A previous study suggested that the expression of 11β-HSD2 is highly tissue-specific in vivo (16). 11β-HSD2 is highly expressed in target organs containing mineralocorticoid receptors that are involved in mediating steroid resistance, and the tissue-specific profile of 11β-HSD2 expression has been attributed to differential methylation of the CpG island-rich 11β-HSD2 promoter (16,30). Sp1 domain B is a high affinity DNA-binding structure that includes a PKA-compliant phosphorylation site at Thr366 (31). The cAMP/PKA signaling pathway regulates the transactivation of Sp1 and DNA-binding activity, and PKA stimulates transcription of the Sp1-dependent promoter in intact cells and activates the DNA-binding activity of Sp1 in vitro (32). In a study investigating the mechanism by which the placental glucocorticoid barrier is established, it was reported that human chorionic gonadotropin altered histone modification and increased the expression of Sp1 via activation of the cAMP/PKA signaling pathway, which activated 11β-HSD2 transcription (33). A further study demonstrated that 11β-HSD2 expression was influenced by increased Sp1 expression following activation of the cAMP signaling pathway, rather than the differential methylation of the 11β-HSD2 promoter (20). The interaction between Sp1 and PKA is similar to the complex formed between the PKA catalytic subunit and NF-κB (34). Another previous study reported that Sp1 is the substrate of DNA-dependent protein kinase in vitro, and is phosphorylated at multiple sites in HeLa nuclear extract; however, the study did not determine the degree of DNA binding, or Sp1-dependent transcription or specificity (35).

A previous study confirmed the expression of 11β-HSD2 in necrotic tissue of the femoral head, which was increased in a model of steroid-induced femoral head necrosis, whereas the expression of 11β-HSD2 was decreased (22). Furthermore,
it was reported that when the transected recombinant adenovirus Ad-Iβ-HSD2 entered into MLO-Y4 and MC3T3-E1 cells, the expression of Iβ-HSD2 was upregulated, and the number of apoptotic cells and the relative expression of apoptotic proteins decreased, reflecting a decrease in apoptosis (12). However, the regulatory mechanism underlying Iβ-HSD2 has not been previously reported.  

In the present study, forskolin and SQ22536 were used as cAMP activator and inhibitor, respectively. ELISA was performed to identify alterations to intracellular cAMP content, and RT-qPCR and western blotting were performed to measure the relative expression levels of Sp1 and Iβ-HSD2. Compared with the negative control group, the expression levels of Sp1 and Iβ-HSD2 were significantly increased in the activator group, and the opposite results were observed in the inhibitor group. The results preliminarily suggested that the expression of Sp1 and Iβ-HSD2 was regulated by cAMP in osteocytes and osteoblasts. However, the mechanism underlying Sp1-mediated regulation of Iβ-HSD2 was not identified. Sp1 regulates gene expression via two main mechanisms. One mechanism involves recruitment of basic transcriptional device proteins and direct interaction with certain proteins in transcriptional complexes, which activates gene transcription by recruiting or promoting the assembly of the basic transcription device (36). The other mechanism involves alterations to chromosome modification. Sp1 can recruit histone acety-lase and deacetylase to regulate the acetylation state of the histone at the gene promoter, thereby activating or inhibiting gene expression (37). However, Sp1-mediated regulation of Iβ-HSD2 expression requires further investigation.

Apoptosis is an important mechanism associated with steroid-induced femoral head necrosis; furthermore, osteocyte and osteoblast apoptosis result in reduced bone formation, as well as inadequate bone remodeling and repair (38). The aim of the present study was to identify a potential mechanism underlying Iβ-HSD2 involvement in steroid-induced bone necrosis at the cellular level. However, combinations of Sp1 and Iβ-HSD2 promoter regions, post-modification alterations and interactions in vivo have not yet been studied; therefore, future studies are required.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Health and Family Planning Commission of Hubei Province (grant no. WJ2018H0002).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

ZP made substantial contributions to the conception and design of the current study and gave final approval of the version to be published. DL analyzed and interpreted data, and drafted the manuscript. DL, YW, ZH and FC performed the experiments. ZP supervised the project. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Wang A, Ren M, Song Y, Wang X, Wang Q, Yang Q, Liu H, Du Z, Zhang G and Wang J: MicroRNA expression profiling of bone marrow mesenchymal stem cells in steroid-induced osteonecrosis of the femoral head associated with osteogenesis. Med Sci Monit 24: 1813-1825, 2018.
2. Weinstein RS: Glucocorticoid-induced osteonecrosis. Endocrine 41: 183-190, 2012.
3. Xu J, Gong H, Lu S, Deasey MJ and Cui Q: Animal models of steroid-induced osteonecrosis of the femoral head-a comprehensive research review up to 2018. Int Orthop 42: 1729-1737, 2018.
4. Luo P, Gao F, Han J, Sun W and Li Z: The role of autophagy in steroid necrosis of the femoral head: A comprehensive research review. Int Orthop 42: 1747-1755, 2018.
5. Deng S, Zhou JL, Fang HS, Nie ZG, Chen S and Peng H: Sesamin protects the femoral head from osteonecrosis by inhibiting ROS-induced osteoblast apoptosis in rat model. Front Physiol 9: 1787, 2018.
6. Youm Y-S, Lee S-Y and Lee S-H: Apoptosis in the osteonecrosis of the femoral head. Clin Orthop Surg 2: 250-255, 2010.
7. Sato AY, Tu X, McAndrews KA, Plotkin LI and Bellido T: Prevention of glucocorticoid-induced-apoptosis of osteoblasts and osteocytes by protecting against endoplasmic reticulum (ER) stress in vitro and in vivo in female mice. Bone 73: 60-68, 2015.
8. Mutijima E, De Maertelaer V, Deprez M, Malaise M and Hauzuer JP: The apoptosis of osteoblasts and osteocytes in femoral head osteonecrosis: Its specificity and its distribution. Clin Rheumatol 33: 1791-1795, 2014.
9. Weinstein RS, Nicholas RW and Manolagas SC: Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 85: 2907-2912, 2000.
10. Komori T: Glucocorticoid Signaling and Bone Biology. Horm Metab Res 48: 755-763, 2016.
11. Lu C, Meng S, Jin Y, Zhang W, Li Z, Wang F, Wang-Johanning F, Wei Y, Liu H, Tu H, et al: A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy. Br J Haematol 178: 413-426, 2017.
12. Zhang H, Zhou F, Pan Z, Bu X, Wang Y and Chen F: Iβ-hydroxysteroid dehydrogenases-2 decreases the apoptosis of MC3T3/MLO-Y4 cells induced by glucocorticoids. Biochem Biophys Res Commun 490: 1399-1406, 2017.
13. Zhou HY, Chen XX, Lin H, Fei AL and Ge RS: Iβ-hydroxysteroid dehydrogenase types 1 and 2 in postnatal development of rat testis: Gene expression, localization and regulation by luteinizing hormone and androgens. Asian J Androl 16: 811-816, 2014.
14. Li X, Mao B, Dong Y, Li Y, Zhan M, Bui Y, Lian Q, Ge RS and Ye L: Effects of ziram on rat and human Iβ-hydroxysteroid dehydrogenase isoforms. Chem Res Toxicol 29: 398-405, 2016.
15. Chapman K, Holmes M and Seckl J: Iβ-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev 93: 1139-1206, 2013.
16. Draper N and Stewart PM: Iβ-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 186: 251-271, 2005.
17. Nawrocki AR, Goldring CE, Kostadinova RM, Frey FJ and Frey BM: In vivo footprinting of the human 11β-hydroxysteroid dehydrogenase type 2 promoter: Evidence for cell-specific regulation by Sp1 and Sp3. J Biol Chem 277: 14647-14656, 2002.

18. Black AR, Black JD and Azizkhan-Clifford J: Sp1 and krüppel-like family of transcription factors in cell growth regulation and cancer. J Cell Physiol 188: 143-160, 2001.

19. Kasai B, Gaumond MH and Moffitt P: Regulation of the bone-restricted IFITM-like (Bril) gene transcription by Sp and Gli family members and CpG methylation. J Biol Chem 288: 13278-13294, 2013.

20. Li JN, Ge YC, Yang Z, Guo CM, Duan T, Myatt L, Guan H, Yang K and Sun K: The Sp1 transcription factor is crucial for the expression of 11beta-hydroxysteroid dehydrogenase type 2 in human placental trophoblasts. J Clin Endocrinol Metab 96: E899-E907, 2011.

21. Wang W, Li J, Ge Y, Li W, Shu Q, Guan H, Yang K, Myatt L and Sun K: Cortisol induces aromatase expression in human placental syncytiotrophoblasts through the cAMP/Sp1 pathway. Endocrinology 153: 2012-2022, 2012.

22. Wang L, Luo D and Pan ZY: Expression of 11β-HSD in steroid-induced avascular necrosis of the femoral head. Mol Med Rep 7: 1482-1486, 2013.

23. Sun T, Yan Z, Cai J, Shao X, Wang D, Ding Y, Feng Y, Yang J, Luo E, Feng X, et al: Effects of mechanical vibration on cell morphology, proliferation, apoptosis, and cytokine expression/secretion in osteocyte-like MLO-Y4 cells exposed to high glucose. Cell Biol Int: Aug 26, 2019 (Epub ahead of print).

24. Czekanska EM, Stoddart MJ, Richards RG and Hayes JS: In search of an osteoblast cell model for in vitro research. Eur Cell Mater 24: 1-17, 2012.

25. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.

26. Cabrera-Sharp V, Mirczuk SM, Shervill E, Michael AE and Fowkes RC: Regulation of glucocorticoid metabolism in the boar testis and caput epididymis by the gonadotrophin-cAMP signalling pathway. Cell Tissue Res 352: 751-760, 2013.

27. Yu L, Zhou J, Zhang G, Huang W, Pei L, Lv F, Zhang Y, Zhang W and Wang H: cAMP/PKA/EGR1 signaling mediates the molecular mechanism of ethanol-induced inhibition of placental 11β-HSD2 expression. Toxicol Appl Pharmacol 352: 77-86, 2018.

28. Pizzolo F, Friso S, Morandini F, Antoniazzi F, Zaltron C, Udali S, Gandini A, Cavazzere P, Salvagno G, Giorgetti A, et al: Apparent mineralocorticoid excess by a novel mutation and epigenetic modulation by HSD11B2 promoter methylation. J Clin Endocrinol Metab 100: E1234-E1241, 2015.

29. Pan F, Shen W, Wu S, Chen N, Tong X, Wang F and Zhang Q: Sp1 participates in the cadmium-induced imbalance of the placental glucocorticoid barrier by suppressing 11β-HSD2 expression. Environ Pollut 261: 1-12, 2020.

30. Alikhani-Koopaei R, Fouladkou F, Frey FJ and Frey BM: Epigenetic regulation of 11β-hydroxysteroid dehydrogenase type 2 expression. J Clin Invest 114: 1146-1157, 2004.

31. Chu S: Transcriptional regulation by post-transcriptional modification - role of phosphorylation in Sp1 transcriptional activity. Gene 508: 1-8, 2012.

32. Rohlf C, Ahmad S, Borellini F, Lei J and Glazer RI: Modulation of transcription factor Sp1 by cAMP-dependent protein kinase. J Biol Chem 272: 21137-21141, 1997.

33. Zhu P, Wang W, Zuo R and Sun K: Mechanisms for establishment of the placental glucocorticoid barrier, a guard for life. Cell Mol Life Sci 76: 13-26, 2019.

34. Zhong H, SuYang H, Erdjument-Bromage H, Tempst P and Ghosh S: The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclical AMP-independent mechanism. Cell 89: 413-424, 1997.

35. Jackson SP, MacDonald JJ, Lees-Miller S and Tjian R: GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase. Cell 63: 155-165, 1990.

36. Taatjes DJ and Tjian R: Structure and function of CRSP/Med2; a promoter-selective transcriptional coactivator complex. Mol Cell 14: 675-683, 2004.

37. Hung JJ, Wang VT and Chang WC: Sp1 deacetylation induced by phorbol ester recruits p300 to activate 12(S)-lipoxygenase gene transcription. Mol Cell Biol 26: 1770-1785, 2006.

38. Kothapalli R, Aya-ay JP, Bhan H, Garces A and Kim HK: Ischaemic injury to femoral head induces apoptotic and oncotic cell death. Pathology 39: 241-246, 2007.